Program
Anti-ROR1/Anti-CD3 Bispecific Antibody EMB-07
Its studies are mostly in Lymphoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| EpimAb Biotherapeutics (Suzhou)its history only | 11 open or running | phase 1since Oct 27, 2022 | Oct 27, 2022 | none ahead |
| Shanghai EpimAb Biotherapeuticsits history only | 11 open or running | phase 2since Feb 6, 2026 | Feb 6, 2026 | Jun 30, 2028phase 2 · NCT07432022 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 27, 2022First study: phase 1 study in RecurrenceNew to EpimAb Biotherapeutics (Suzhou)EpimAb Biotherapeutics (Suzhou) · NCT05607498 · 150 planned · Australia, China
- Feb 6, 2026Shanghai EpimAb Biotherapeutics’ first study: phase 2 study in Combination TherapyNew to Shanghai EpimAb BiotherapeuticsShanghai EpimAb Biotherapeutics · NCT07432022 · 115 planned · China
Ahead
- Jun 30, 2028Primary completion: phase 2 study in Combination TherapyShanghai EpimAb Biotherapeutics · NCT07432022
TargetBeta
“A bispecific antibody directed against both the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) and the T-cell surface antigen CD3, ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07432022Combination Therapy · China | 2 | Recruiting | Shanghai EpimAb Biotherapeutics | Jun 30, 2028 | 115 |
| NCT05607498Recurrence · Australia, China | 1 | Recruiting | EpimAb Biotherapeutics (Suzhou) | Oct 31, 2025 | 150 |
How it is read
Names in the registry
- “EMB07”, 2 entries
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.